Avenue Therapeutics Q4 EPS $(0.98) Misses $(0.10) Estimate
Portfolio Pulse from Happy Mohamed
Avenue Therapeutics (NASDAQ:ATXI) reported a Q4 EPS loss of $(0.98), missing the consensus estimate of $(0.10) by 880%, but marking a 20.33% improvement over last year's $(1.23) loss per share.
March 18, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avenue Therapeutics reported a significant miss in Q4 EPS, with a loss of $(0.98) compared to the $(0.10) estimate, yet showed improvement from the previous year.
The significant miss in earnings per share (EPS) compared to analyst estimates is likely to negatively impact investor sentiment and the stock price in the short term. However, the improvement from the previous year's loss indicates some progress, which might mitigate the negative impact slightly.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100